# Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)

> **NCT07354061** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 20 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** Ensartinib + Chemotherapy

## Key facts

- **NCT ID:** NCT07354061
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-25
- **Primary completion:** 2028-03-25
- **Final completion:** 2030-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07354061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07354061, "Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07354061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*